References
- Center for Drug Evaluation and Research. Drug-induced liver injury: premarketing clinical evaluation [Internet]. Silver Spring (MD): U.S. Food and Drug Administration (USFDA); 2009. [cited 2023 May 10]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-induced-liver-injury-premarketing-clinical-evaluation.
- FDA-NIH Biomarker Working Group. BEST (biomarkers, EndpointS, and other tools) resource (Internet). Silver Spring (MD): U.S. Food and Drug Administration (USFDA); 2016–20. Glossary. 2016 Jan 28. Updated 2020 Mar 3. (Webpage)
- Council for International Organisations of Medical Sciences. Drug-induced liver injury (DILI): current status and future directions for drug development and the post-market setting; 2020.
- Critical Path Institute (C-Path) Predictive Safety Testing Consortium’s (PSTC) Hepatocyte Working Group (HWG). Qualification plan for glutamate dehydrogenase (GLDH) as a biomarker of drug induced liver injury in individuals with skeletal muscle degeneration; 2020.
- McGill MR. The past and present of serum aminotransferases and the future of liver injury biomarkers. EXCLI J. 2016;15:817–828.
- Senior JR. Alanine aminotransferase: a clinical and regulatory tool for detecting liver injury–past, present, and future. Clin Pharmacol Ther. 2012;92(3):332–339. doi:10.1038/clpt.2012.108.
- Brennan P, Cartlidge P, Manship T, et al. Guideline review: EASL clinical practice guidelines: drug-induced liver injury (Dili). Frontline Gastroenterol. 2022;13(4):332–336. doi:10.1136/flgastro-2021-101886.
- Dear JW, Clarke JI, Francis B, et al. Risk stratification after paracetamol overdose using mechanistic biomarkers: results from two prospective cohort studies. Lancet Gastroenterol Hepatol. 2018;3(2):104–113. doi:10.1016/S2468-1253(17)30266-2.
- Gromova M, Vaggelas A, Dallmann G, et al. Biomarkers: opportunities and challenges for drug development in the current regulatory landscape. Biomark Insights. 2020;15:1177271920974652. doi:10.1177/1177271920974652.
- Medicines and Healthcare products Regulatory Agency. In vitro diagnostic medical devices: guidance on legislation [Internet]. 2020. [cited 2023 May 10]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/946260/IVDD_legislation_guidance_-_PDF.pdf.
- https://www.fda.gov/drugs/biomarker-qualification-program/about-biomarkers-and-qualification#:∼:text=biomarker%20measurement%20method.-,How%20are%20biomarkers%20qualified%20for%20drug%20development%3F,develop%20a%20biomarker%20for%20qualification.
- Bonkovsky HL, Severson T, Nicoletti P, et al. Genetic polymorphisms implicated in nonalcoholic liver disease or selected other disorders have no influence on Drug-Induced liver injury. Hepatol Commun. 2019;3(8):1032–1035. doi:10.1002/hep4.1382.
- Aleo MD, Luo Y, Swiss R, et al. Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump. Hepatology. 2014;60(3):1015–1022. doi:10.1002/hep.27206.
- Mosedale M, Watkins P. Drug-induced liver injury: advances in mechanistic understanding that will inform risk management. Clin Pharmacol Ther. 2017;101(4):469–480. doi:10.1002/cpt.564.
- Hendrickson R, McKeown N, et al. Acetaminophen. In: Nelson L, Howland M, Lewin N, editors. Goldfrank’s toxicologic emergencies. 11th ed. New York (NY): McGraw-Hill Education; 2019. p. 472–491.
- Urban TJ, Goldstein DB, Watkins PB. Genetic basis of susceptibility to drug-induced liver injury: what have we learned and where do we go from here? Pharmacogenomics. 2012;13(7):735–738. doi:10.2217/pgs.12.45.
- Kullak-Ublick GA, Andrade RJ, Merz M, et al. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut. 2017;66(6):1154–1164. doi:10.1136/gutjnl-2016-313369.
- Ostapowicz G, Fontana RJ, Schiødt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137(12):947–954. doi:10.7326/0003-4819-137-12-200212170-00007.
- Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. Arch Intern Med. 2005;165(12):1363–1369. doi:10.1001/archinte.165.12.1363.
- Memon A, Yeboah-Korang A, Fontana RJ. Advances in the management of idiosyncratic drug-induced liver injury. Clin Liver Dis. 2023;21(4):102–106. doi:10.1097/CLD.0000000000000052.
- Food and Drug Administration. Letter-of-support-for-drug-induced-liver-injury-(DILI)-biomarker(s)-7-25-16.pdf [Internet]. [cited 2023 May 11]. Available from: https://fda.report/media/99532/Letter-of-Support-for-Drug-Induced-Liver-Injury-%28DILI%29-Biomarker%28s%29-7-25-16.pdf.
- European Medicines Agency. Retraction of the “Letter of support for drug-induced liver injury (DILI) biomarker” (EMA/423870/2016) [Internet]. [cited 2023 May 11]. Available from: https://www.ema.europa.eu/en/documents/other/retraction-letter-support-drug-induced-liver-injury-dili-biomarker-ema/423870/2016_en.pdf.
- Antoine DJ, Jenkins RE, Dear JW, et al. Retraction notice to “molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity. J Hepatol. 2020;73(5):1297. doi:10.1016/j.jhep.2020.08.022.
- Schofield AL, Brown JP, Brown J, et al. Systems analysis of miRNA biomarkers to inform drug safety. Arch Toxicol. 2021;95(11):3475–3495. doi:10.1007/s00204-021-03150-9.
- Llewellyn HP, Vaidya VS, Wang Z, et al. Evaluating the sensitivity and specificity of promising circulating biomarkers to diagnose liver injury in humans. Toxicol Sci. 2021;181(1):23–34. doi:10.1093/toxsci/kfab003.
- Church RJ, Kullak-Ublick GA, Aubrecht J, et al. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: an international collaborative effort. Hepatology. 2019;69(2):760–773. doi:10.1002/hep.29802.
- Church RJ, Watkins PB. Serum biomarkers of drug-induced liver injury: current status and future directions. J Dig Dis. 2019;20(1):2–10. doi:10.1111/1751-2980.12684.
- Roth S, Avigan M, Bourdet D, et al. Next generation Dili biomarkers: prioritization of biomarkers for qualification and best practices for biospecimen collection in drug development. Clin Pharmacol Ther. 2020;107(2):333–346. doi:10.1002/cpt.1571.
- Stutchfield BM, Antoine DJ, Mackinnon AC, et al. CSF1 restores innate immunity after liver injury in mice and serum levels indicate outcomes of patients with acute liver failure. Gastroenterology. 2015;149(7):1896–1909.e14. doi:10.1053/j.gastro.2015.08.053.
- ] Bandiera S, Pfeffer S, Baumert TF, et al. miR-122–a key factor and therapeutic target in liver disease. J Hepatol. 2015;62(2):448–457. doi:10.1016/j.jhep.2014.10.004.
- Morrison EE, Oatey K, Gallagher B, et al. Principal results of a randomized open label exploratory, safety and tolerability study with calmangafodipir in patients treated with a 12 h regimen of N-acetylcysteine for paracetamol overdose (POP trial). eBioMedicine. 2019;46:423–430. doi:10.1016/j.ebiom.2019.07.013.
- Moore JK, MacKinnon AC, Man TY, et al. Patients with the worst outcomes after paracetamol (acetaminophen)-induced liver failure have an early monocytopenia. Aliment Pharmacol Ther. 2017;45(3):443–454. doi:10.1111/apt.13878.
- Woolbright BL, Nguyen NT, McGill MR, et al. Generation of pro-and anti-inflammatory mediators after acetaminophen overdose in surviving and non-surviving patients. Toxicol Lett. 2022;367:59–66. doi:10.1016/j.toxlet.2022.07.813.
- McDonaugh B, Whyte MB. The evolution and future direction of the cardiac biomarker. EMJ Cardiol. 2020;8(1):97–106. doi:10.33590/emjcardiol/20-00045.
- Holman NS, Mosedale M, Wolf KK, et al. Subtoxic alterations in Hepatocyte-Derived exosomes: an early step in Drug-Induced liver injury? Toxicol Sci. 2016;151(2):365–375. doi:10.1093/toxsci/kfw047.
- Heise CW, Gallo T, Curry SC, et al. Identification of populations likely to benefit from pharmacogenomic testing. Pharmacogenet Genomics. 2020;30(5):91–95. doi:10.1097/FPC.0000000000000400.
- Court MH, Peter I, Hazarika S, et al. Candidate gene polymorphisms in patients with acetaminophen-induced acute liver failure. Drug Metab Dispos. 2014;42(1):28–32. doi:10.1124/dmd.113.053546.